` CMPX (Compass Therapeutics Inc.) vs S&P 500 Comparison - Alpha Spread

C
CMPX
vs
S&P 500

Over the past 12 months, CMPX has significantly outperformed S&P 500, delivering a return of +230% compared to the S&P 500's +14% growth.

Stocks Performance
CMPX vs S&P 500

Loading
CMPX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CMPX vs S&P 500

Loading
CMPX
S&P 500
Difference
www.alphaspread.com

Performance By Year
CMPX vs S&P 500

Loading
CMPX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Compass Therapeutics Inc. vs Peers

S&P 500
CMPX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Compass Therapeutics Inc.
Glance View

Market Cap
886.1m USD
Industry
Biotechnology

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).

CMPX Intrinsic Value
1.82 USD
Overvaluation 63%
Intrinsic Value
Price
C
Back to Top